{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:11:05Z","timestamp":1794816665472,"version":"4.9.1"},"reference-count":38,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation MI (NSTEMI). Experimental studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory mechanisms, but this has not been tested in clinical studies. With the <jats:italic>ASS<\/jats:italic>essing the effect of <jats:italic>A<\/jats:italic>nti-<jats:italic>IL<\/jats:italic>-6 treatment in <jats:italic>MI<\/jats:italic> (ASSAIL-MI) trial, we aim to examine whether a single administration of the IL-6 receptor antagonist tocilizumab can increase myocardial salvage in patients with acute ST-elevation MI (STEMI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>The ASSAIL-MI trial is a randomised, double blind, placebo-controlled trial, conducted at three high-volume percutaneous coronary intervention (PCI) centres in Norway. 200 patients with first-time STEMI presenting within 6\u2009hours of the onset of chest pain will be randomised to receive tocilizumab or matching placebo prior to PCI. The patients are followed-up for 6 months. The primary endpoint is the myocardial salvage index measured by cardiac MRI (CMR) 3\u20137 days after the intervention. Secondary endpoints include final infarct size measured by CMR and plasma markers of myocardial necrosis. Efficacy and safety assessments during follow-up include blood sampling, echocardiography and CMR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Based on previous experience the study is considered feasible and safe. If tocilizumab increases myocardial salvage, further endpoint-driven multicentre trials may be initiated. The ASSAIL-MI trial has the potential to change clinical practice in patients with STEMI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>Clinicaltrials.gov, identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03004703\">NCT03004703<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2019-001108","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T06:54:15Z","timestamp":1571208855000},"page":"e001108","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":48,"title":["Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct03004703","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-2402","authenticated-orcid":false,"given":"Anne Kristine","family":"Anstensrud","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindre","family":"Woxholt","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"},{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Broch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Bendz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Aakhus","sequence":"additional","affiliation":[{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"K.G.Jebsen Thrombosis Research and Expertise Center (TREC), The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brage H","family":"Amundsen","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"},{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Kristian","family":"Dam\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St. Olavs Hospital, Trondheim University Hospital, Oslo, Norway"},{"name":"Department of Clinical and Molecular Medicine, Centre of Molecular Inflammation Research, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Hopp","sequence":"additional","affiliation":[{"name":"Division of Radiology and Nuclear Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Kleveland","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"},{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut Haakon","family":"Stens\u00e6th","sequence":"additional","affiliation":[{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Opdahl","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils-Einar","family":"Kl\u00f8w","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Radiology, Oslo University Hospital Ullevaal, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingebj\u00f8rg","family":"Seljeflot","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital Ullevaal, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir \u00d8ystein","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway"},{"name":"Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital Ullevaal, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Wiseth","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"},{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Rheumatology, Dermatology and Infectious Disease, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2025081710155531000_6.2.e001108.1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/ehx628","article-title":"European Society of cardiology: cardiovascular disease statistics 2017","volume":"39","author":"Timmis","year":"2018","journal-title":"Eur Heart J"},{"key":"2025081710155531000_6.2.e001108.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000558"},{"key":"2025081710155531000_6.2.e001108.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw171"},{"key":"2025081710155531000_6.2.e001108.4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","article-title":"Reassessing the mechanisms of acute coronary syndromes","volume":"124","author":"Libby","year":"2019","journal-title":"Circ Res"},{"key":"2025081710155531000_6.2.e001108.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112160"},{"key":"2025081710155531000_6.2.e001108.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071667"},{"key":"2025081710155531000_6.2.e001108.7","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.11.2844"},{"key":"2025081710155531000_6.2.e001108.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043430"},{"key":"2025081710155531000_6.2.e001108.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025081710155531000_6.2.e001108.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu272"},{"key":"2025081710155531000_6.2.e001108.11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/clc.22988","article-title":"Rationale and design of the Virginia Commonwealth University-Anakinra remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study","volume":"41","author":"Van Tassell","year":"2018","journal-title":"Clin Cardiol"},{"key":"2025081710155531000_6.2.e001108.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000087447.12918.85"},{"key":"2025081710155531000_6.2.e001108.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505489"},{"key":"2025081710155531000_6.2.e001108.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000087404.53661.F8"},{"key":"2025081710155531000_6.2.e001108.15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017611"},{"key":"2025081710155531000_6.2.e001108.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.003"},{"key":"2025081710155531000_6.2.e001108.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3609"},{"key":"2025081710155531000_6.2.e001108.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-010-0361-1"},{"key":"2025081710155531000_6.2.e001108.19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091404.09558.AF"},{"key":"2025081710155531000_6.2.e001108.20","doi-asserted-by":"publisher","DOI":"10.2174\/157340308785160570"},{"key":"2025081710155531000_6.2.e001108.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9431-1"},{"key":"2025081710155531000_6.2.e001108.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.12.024"},{"key":"2025081710155531000_6.2.e001108.23","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011401825680"},{"key":"2025081710155531000_6.2.e001108.24","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq078"},{"key":"2025081710155531000_6.2.e001108.25","doi-asserted-by":"crossref","unstructured":"Ritschel VN , Seljeflot I , Arnesen H , et al . Circulating levels of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. J Am Heart Assoc 2016;5. doi:doi:10.1161\/JAHA.115.003014","DOI":"10.1161\/JAHA.115.003014"},{"key":"2025081710155531000_6.2.e001108.26","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2025081710155531000_6.2.e001108.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025081710155531000_6.2.e001108.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000042674.89762.20"},{"key":"2025081710155531000_6.2.e001108.29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijcard.2018.06.093","article-title":"Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction","volume":"274","author":"Ueland","year":"2019","journal-title":"Int J Cardiol"},{"key":"2025081710155531000_6.2.e001108.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.06.1194"},{"key":"2025081710155531000_6.2.e001108.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.12.027"},{"key":"2025081710155531000_6.2.e001108.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu331"},{"key":"2025081710155531000_6.2.e001108.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003653"},{"key":"2025081710155531000_6.2.e001108.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv463"},{"key":"2025081710155531000_6.2.e001108.35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.amjcard.2015.06.034","article-title":"Six-Year prognostic value of microvascular obstruction after reperfused ST-elevation myocardial infarction as assessed by contrast-enhanced cardiovascular magnetic resonance","volume":"116","author":"Regenfus","year":"2015","journal-title":"Am J Cardiol"},{"key":"2025081710155531000_6.2.e001108.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055706"},{"key":"2025081710155531000_6.2.e001108.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.071"},{"key":"2025081710155531000_6.2.e001108.38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002708","article-title":"Sample size in clinical cardioprotection trials using myocardial salvage index, infarct size, or biochemical markers as endpoint","volume":"5","author":"Engblom","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2019-001108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:16:05Z","timestamp":1755450965000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2019-001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,15]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/openhrt-2019-001108"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2019-001108","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}